These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 29395795)

  • 61. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging.
    Grueneisen J; Nagarajah J; Buchbender C; Hoffmann O; Schaarschmidt BM; Poeppel T; Forsting M; Quick HH; Umutlu L; Kinner S
    Invest Radiol; 2015 Aug; 50(8):505-13. PubMed ID: 26115367
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
    Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
    Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The utility of [18F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours.
    Fukumoto K; Taniguchi T; Ishikawa Y; Kawaguchi K; Fukui T; Kato K; Matsuo K; Yokoi K
    Eur J Cardiothorac Surg; 2012 Dec; 42(6):e152-6. PubMed ID: 23024234
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study.
    Schwenzer NF; Schraml C; Müller M; Brendle C; Sauter A; Spengler W; Pfannenberg AC; Claussen CD; Schmidt H
    Radiology; 2012 Aug; 264(2):551-8. PubMed ID: 22653189
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI.
    Theruvath AJ; Siedek F; Muehe AM; Garcia-Diaz J; Kirchner J; Martin O; Link MP; Spunt S; Pribnow A; Rosenberg J; Herrmann K; Gatidis S; Schäfer JF; Moseley M; Umutlu L; Daldrup-Link HE
    Radiology; 2020 Jul; 296(1):143-151. PubMed ID: 32368961
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT.
    Herrmann K; Queiroz M; Huellner MW; de Galiza Barbosa F; Buck A; Schaefer N; Stolzman P; Veit-Haibach P
    BMC Cancer; 2015 Dec; 15():1002. PubMed ID: 26699124
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study.
    Jouvet JC; Thomas L; Thomson V; Yanes M; Journe C; Morelec I; Bracoud L; Durupt F; Giammarile F; Berthezene Y
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):176-85. PubMed ID: 23331931
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology.
    Antoch G; Vogt FM; Freudenberg LS; Nazaradeh F; Goehde SC; Barkhausen J; Dahmen G; Bockisch A; Debatin JF; Ruehm SG
    JAMA; 2003 Dec; 290(24):3199-206. PubMed ID: 14693872
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma.
    Rockall AG; Barwick TD; Wilson W; Singh N; Bharwani N; Sohaib A; Nobbenhuis M; Warbey V; Miquel M; Koh DM; De Paepe KN; Martin-Hirsch P; Ghaem-Maghami S; Fotopoulou C; Stringfellow H; Sundar S; Manchanda R; Sahdev A; Hackshaw A; Cook GJ;
    Clin Cancer Res; 2021 Dec; 27(23):6457-6466. PubMed ID: 34526364
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients.
    Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K
    Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma.
    Mistry V; Scott JR; Wang TY; Mollee P; Miles KA; Law WP; Hapgood G
    Cancer Imaging; 2023 Jan; 23(1):11. PubMed ID: 36694244
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Optimization of whole-body 2-[
    Burns R; Mulé S; Blanc-Durand P; Tofighi M; Belhadj K; Zerbib P; Le Bras F; Baranes L; Haioun C; Itti E; Luciani A
    Eur Radiol; 2022 May; 32(5):3085-3096. PubMed ID: 34842956
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.
    Bruckmann NM; Kirchner J; Morawitz J; Umutlu L; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Ingenwerth M; Schaarschmidt BM; Li Y; Stang A; Antoch G; Sawicki LM; Buchbender C
    PLoS One; 2021; 16(12):e0260804. PubMed ID: 34855886
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The role of [¹⁸F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors.
    Kaira K; Sunaga N; Ishizuka T; Shimizu K; Yamamoto N
    Cancer Imaging; 2011 Nov; 11(1):195-201. PubMed ID: 22138614
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies.
    Regacini R; Puchnick A; Shigueoka DC; Iared W; Lederman HM
    Sao Paulo Med J; 2015; 133(2):141-50. PubMed ID: 25789779
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 18F-FDG-PET/CT predicts grade of malignancy and invasive potential of thymic epithelial tumors.
    Ito T; Suzuki H; Sakairi Y; Wada H; Nakajima T; Yoshino I
    Gen Thorac Cardiovasc Surg; 2021 Feb; 69(2):274-281. PubMed ID: 32734427
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
    Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
    Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Diagnostic Significance of 18F-FDG PET/CT Imaging Coupled with Magnetic Resonance Imaging of the Entire Body for Bone Metastases.
    Guo H; Zhang Z; Wang L; Yao S; Xu S; Ma S; Liu S
    Contrast Media Mol Imaging; 2022; 2022():7717398. PubMed ID: 36247843
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Simultaneous whole-body ¹⁸F-FDG PET-MRI in primary staging of breast cancer: a pilot study.
    Taneja S; Jena A; Goel R; Sarin R; Kaul S
    Eur J Radiol; 2014 Dec; 83(12):2231-2239. PubMed ID: 25282709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.